Drug

Vunakizumab clinical trials

Also written SHR-1314.

studies test it: 19
open now: 5
in phase 3: 5
first study started: 2016

Keep track of what changes. Save the vunakizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SHR-1314 injection: 3
Vunakizumab (IL-17A inhibitor): 3

Development codes

SHR-1314: 13

Studies by the year they started

19 studies that test it; most in 2025 (5)

Studies that test vunakizumab, by start year
Year	Studies
2016	1
2017	1
2018	2
2019	1
2020	2
2021	4
2022	1
2023	1
2024	1
2025	5

By phase

A phase 1/2 study counts in both.

Phase 1: 8
Phase 2: 7
Phase 3: 5
Phase 4: 1

What it is tested for

Each study’s main condition, where its own words name it.

Psoriasis: 5
Arthritis, Psoriatic: 2
Spondylitis, Ankylosing: 1
Axial Spondyloarthritis: 1
Small Cell Lung Carcinoma: 1
Lupus Erythematosus, Systemic: 1
Non-Radiographic Axial Spondyloarthritis: 1
Graves Ophthalmopathy: 1
Lupus Nephritis: 1

Who runs them

Industry 17 · Other 2

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (9) · Jiangsu HengRui Medicine Co., Ltd. (7) · Atridia Pty Ltd. (1) · Fujian Cancer Hospital (1) · Chinese SLE Treatment And Research Group (1)

Often tested with

Tested in the same studies.

Adebrelimab (1) · Antineoplastic Agents (1)

Studies

Open first, then newest update. How each study uses vunakizumab is read from its arms, and is right about nine times in ten.

Testing it · 19

Codes

What other systems call vunakizumab · ClinicalTrials.gg INT018546

UNII (FDA) Y4U029R8MSVUNAKIZUMABOne source FDA
NCI Thesaurus C152923VunakizumabOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	Y4U029R8MS	VUNAKIZUMAB	One source FDA
NCI Thesaurus	C152923	Vunakizumab	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.